Top

Published in:

01-07-2015 | Case Report

A case of fatal intoxication due to the new designer drug 25B-NBOMe

Authors: Ken-ichi Yoshida, Kanju Saka, Kaori Shintani-Ishida, Hideyuki Maeda, Makoto Nakajima, Shu-ichi Hara, Masahide Ueno, Katsunori Sasaki, Hirotaro Iwase, Tetsuya Sakamoto

Published in: Forensic Toxicology | Issue 2/2015

Abstract

N-Benzyl-substituted phenethylamines (NBOMes) have emerged as novel hallucinogenic designer drugs with potent serotonin-receptor activation. We present the first scientific case report of fatal intoxication with 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe). The plasma concentration of 25B-NBOMe upon admission was low, 3.15 ng/ml, but it exceeded concentrations reported previously in NBOMe intoxications cases. Our case documents complete clinical and pathophysiological findings that developed shortly after drug ingestion and highlights the danger of 25B-NBOMe use at small doses, based on autopsy and toxicological analyses. The patient presented symptoms consistent with serotonin syndrome.

Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014) Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 32:105–115CrossRef

Papoutsis I, Nikolaou P, Stefanidou M, Spiliopoulou C, Athanaselis S (2015) 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicol 33:1–11CrossRef

Lawn W, Barratt M, Williams M, Horne A, Winstock A (2014) NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 28:780–788PubMedCrossRef

Bersani FS, Corazza O, Albano G, Valeriani G, Santacroce R, Bolzan Mariotti Posocco F, Cinosi E, Simonato P, Martinotti G, Bersani G, Schifano F (2014) 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int 2014:734749. doi:10.1155/2014/734749

Tang MH, Ching CK, Tsui MS, Chu FK, Mak TW (2014) Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol 52:561–565CrossRef

Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin ML, Chen HH, Sanchez LA (2014) Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol 35:20–25PubMedCrossRef

Poklis JL, Devers KG, Arbefeville EF, Pearson JM, Houston E, Poklis A (2014) Postmortem detection of 25I-NBOMe[2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 234:e14–e20PubMedCentralPubMedCrossRef

Sporkert F, Augsburger M, Vilarino R, Michaud K, Schlapfer M, Marcourt L (2013) Identification and implication of the phenethylamine derivative 25B-NBOMe in a case of an unresolved fatality. In: The 51st annual meeting of the International Association of Forensic Toxicologists, Madeira, 2013

Hill SL, Doris T, Gurung S, Katebe S, Lomas A, Dunn M, Blain P, Thomas SHL (2013) Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol 51:487–492CrossRef

10.

Boyer EW, Shannon M (2005) The serotonin syndrome. N Engl J Med 352:1112–1120PubMedCrossRef

11.

Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A (2012) Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care 16:R136. doi:10.1186/cc11441 PubMedCentralPubMedCrossRef

12.

Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A (2005) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6:764–769CrossRef

13.

De Letter EA, Bouche MP, Van Bocxlaer JF, Lambert WE, Piette MH (2004) Interpretation of a 3,4-methylenedioxymethamphetamine (MDMA) blood level: discussion by means of a distribution study in two fatalities. Forensic Sci Int 141:85–90PubMedCrossRef

14.

Braden MR, Parrish JC, Naylor JC, Nichols DE (2006) Molecular interaction of serotonin 5-HT_2A receptor residues Phe339^(6.51) and Phe340^(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70:1956–1964PubMedCrossRef

15.

Juncosa JI Jr, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE (2013) Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT_2A serotonin receptoragonist ligands. ACS Chem Neurosci 4:96–109PubMedCentralPubMedCrossRef

16.

Shioda K, Nisijima K, Yoshino T, Kato S (2010) Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett 482:216–219PubMedCrossRef

17.

Moriya F, Hashimoto Y (1999) Redistribution of basic drugs into cardiac blood from surrounding tissues during early-stages post-mortem. Forensic Sci 44:10–16

Title: A case of fatal intoxication due to the new designer drug 25B-NBOMe
Authors: Ken-ichi Yoshida
Kanju Saka
Kaori Shintani-Ishida
Hideyuki Maeda
Makoto Nakajima
Shu-ichi Hara
Masahide Ueno
Katsunori Sasaki
Hirotaro Iwase
Tetsuya Sakamoto
Publication date: 01-07-2015
Publisher: Springer Japan
Published in: Forensic Toxicology / Issue 2/2015
Print ISSN: 1860-8965
Electronic ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-015-0276-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A case of fatal intoxication due to the new designer drug 25B-NBOMe

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Identification of analogs of LY2183240 and the LY2183240 2′-isomer in herbal products

A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products

Comprehensive review of the detection methods for synthetic cannabinoids and cathinones

Differentiation of regioisomeric chloroamphetamine analogs using gas chromatography–chemical ionization-tandem mass spectrometry

Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues

Simultaneous plasma and oral fluid morphine and codeine concentrations after controlled administration of poppy seeds with known opiate content